The Cerebrovascular Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons and the American Society for Stereotactic and Functional Neurosurgery joined in supporting the Society of Neurological Surgeons newly launched Neurosurgeon-Scientist Training Program.
Researchers at the University of Michigan Rogel Cancer Center have identified a novel treatment approach to an aggressive type of pediatric brain cancer, using therapies already approved to treat cancer. The team developed a mouse model of pediatric glioma with a histone mutation called H3.3-G34, which allowed them to study the tumor’s biology in the presence of a functional immune system, revealing a promising outlook for long-term survival.
Henry Ford Health + Michigan State University Health Sciences today announced its funding of five cancer research grants of up to $100,000 each. These five grants follow an initial wave of funding from the partnership, in which 18 pilot grants of up to $25,000 each were funded in May 2022.
MD Anderson will host the virtual Cancer Neuroscience Symposium Sept. 22-23, 2022, in collaboration with the journal Advanced Biology. The symposium is free to attend and gathers leading experts in the field to discuss a variety of topics on the relationship between cancer biology and neuroscience. Registration includes the opportunity to participate in an abstract competition and to view sessions following the event.
Taken twice daily, oral olutasidenib helped to stabilize relapsed or refractory gliomas in heavily pretreated patients with less toxicity than standard of care treatment, according to a study led by Sylvester Comprehensive Cancer Center at the University of Miami School…
Joseph P. Weiner, MD, radiation oncologist at Rutgers Cancer Institute and assistant professor of radiation oncology at Rutgers Robert Wood Johnson Medical School, who specializes in malignant and benign cancers of the brain and spine shares more about Gamma knife, a non-surgical treatment option that uses high doses of precisely focused radiation beams to destroy cancer cells and non-cancerous tumors.
St. Jude Children’s Research Hospital scientists have identified the primary target of the experimental cancer drug CX-5164, revealing a possible risk for late effects of treatment.
Brain metastasis occurs when cancer in one part of the body spreads to the brain. The lifetime incidence of such metastatic brain tumors in cancer patients is between 20%-45%, research shows.
Dmitri Simberg, PhD, associate professor in the University of Colorado Skaggs School of Pharmacy, released a new study of the effectiveness of different types of fluorescent labels used to monitor the accumulation of liposomes in tumors. The study was published on July 1, 2021, in ACS Nano.
Researchers at Washington University School of Medicine in St. Louis and Stanford University School of Medicine have found that normal exposure to light can drive the formation and growth of optic nerve tumors in mice — and maybe people — with a genetic predisposition. Such tumors can lead to vision loss.
A UCLA-led study published in the peer-reviewed journal Environmental Research suggests that exposure during pregnancy to a wide variety of pesticides may lead to the development of central nervous system tumors during childhood.
Researchers at UAB have identified a potential new pathway to treating radiation-resistant glioblastoma, one of the most aggressive forms of brain cancer. The findings indicate that an adhesive cell surface protein known as N-cad may be key in overcoming glioblastoma’s resistance to radiation therapy.
Scientists say they have discovered a potential new target for immunotherapy of malignant brain tumors, which so far have resisted the ground-breaking cancer treatment based on harnessing the body’s immune system. The discovery, reported in the journal CELL, emerged from laboratory experiments and has no immediate implications for treating patients.
The largest and most detailed molecular analysis yet of an aggressive brain cancer, called glioblastoma, reveals fundamental details that drive its growth. The
A new study led by Washington University School of Medicine in St. Louis has revealed a detailed map of the genes, proteins, infiltrating cells and signaling pathways that play key roles in driving glioblastoma. The study, of 99 tumors from patients, is the largest and most detailed schematic of this deadly brain tumor.
Announcement of articles in the February issue of neurosurgical Focus.
Neuro-oncologist and renowned physician-scientist Ingo Mellinghoff will lead MSK’s distinguished Department of Neurology after previously serving as Acting Co-Chair.
Rutgers Cancer Institute investigator shares about a new project in which 4-dimensional (4D) printing of arrays that transform from cell-culture inserts into histological cassettes are utilized and hold patient tissue samples for rapid programmable drug testing to accelerate treatment testing for glioblastoma multiforme (GBM), a common brain tumor.
The discovery of the oncogene responsible for glioblastoma could be the brain tumor’s Achilles’ heel, one researcher says.
Two new studies led by Renuka Iyer, MD, Section Chief for Gastrointestinal Oncology at Roswell Park Comprehensive Cancer Center, highlight possible new treatment options for patients with neuroendocrine tumors (NETs) — a rare and hard-to-treat cancer.
An innovative use of focused ultrasound is showing promise against glioblastoma, the deadliest brain tumor, and could prove useful against other difficult-to-treat cancers.
UCLA researchers found that adding a drug once commonly used to treat schizophrenia to traditional radiation therapy helped improve overall survival in mice with glioblastoma, one of the deadliest and most difficult-to-treat brain tumors.
An analysis of more than 10,000 gliomas and clinical outcomes reported in Nature by scientists in Boston and Paris found that glioma patients whose tumors were hypermutated actually had no significant benefit when treated with checkpoint blockers.
Scientists at St. Jude Children’s Research Hospital have identified a novel target for a type of pediatric brain tumor.
Researchers trained machine learning algorithms on data from more than 62,000 patients with a meningioma. Their goal was to find statistical associations between malignancy, survival, and a series of basic clinical variables including tumour size, tumour location, and surgical procedure.
Des chercheurs ont entraîné des algorithmes d’apprentissage automatique à partir des données de plus de 62 000 patients ayant un méningiome. L’objectif était de déceler des associations statistiques entre la malignité, le temps de survie et d’autres variables cliniques de base telles que la taille de la tumeur, son emplacement et la nature de l’intervention chirurgicale effectuée.
New basic science and clinical research identifies TAU, the same protein studied in the development of Alzheimer’s, as a biomarker for glioma development.
Two different UC San Diego research teams identified the same molecule — αvβ5 integrin — as Zika virus’ key to brain cell entry. They found ways to take advantage of the integrin to both block Zika virus from infecting cells and turn it into something good: a way to shrink brain cancer stem cells.
Made with extracellular matrix (ECM) from pig brains and seeded with tumors from patients, the system is revealing tumor/ECM interactions that aid tumor growth, providing potential targets for new therapies.
A blood test that measures the amount of cell-free DNA (cfDNA) in the bloodstream – called a liquid biopsy – correlates with how patients will progress after they are diagnosed with glioblastoma (GBM), the deadliest and most common primary brain tumor in adults
NYU Langone Health and its Perlmutter Cancer Center have launched clinical whole genome DNA methylation profiling for patients with brain tumors.
This leading-edge molecular assay utilizes DNA epigenetic signatures and artificial intelligence with machine learning to correctly identify and subtype brain tumors. NYU Langone Health is the first Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in the United States to receive state approval (New York State Department of Health) for whole genome DNA methylation for diagnosis and classification of brain tumors.
When Gary Colon, 51, of Miami, Florida suddenly had trouble speaking, he called his sister, Becky, of Stratford, Connecticut for help. She urged him to go to an emergency department, where he had tests that revealed a meningioma. This large brain tumor was indenting and injuring the speech area of his brain.
Becky quickly made arrangements for Gary to come home and have brain surgery at Norwalk Hospital, where she’s worked for 17 years and knew he would get the best care.
Norwalk Hospital is equipped to handle these types of brain surgery cases because of the highly trained neurosurgeons, and seasoned physician assistants, nurses, medical assistants, operating room staff, and intensive care unit staff who work so well together.
The Congress of Neurological Surgeons Foundation (CNS Foundation) announced a second K12 award will be funded by a generous gift from the Congress of Neurological Surgeons (CNS). The award is made possible through a collaboration with the Foundation of the National Institutes of Health (FNIH) and the National Institutes of Health (NIH).